You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 27, 2024

Details for Patent: RE46284

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent RE46284 protect, and when does it expire?

Patent RE46284 protects LONSURF and is included in one NDA.

This patent has twenty-six patent family members in nineteen countries.

Summary for Patent: RE46284

Title:	Method of administrating an anticancer drug containing .alpha., .alpha., .alpha.-trifluorothymidine and thymidine phosphorylase inhibitor
Abstract:	The present invention relates to a method for treating a cancer comprising orally administering a composition containing .alpha.,.alpha.,.alpha.-trifluorothymidine (FTD) and 5-chloro-6-(1-(2-iminopyrrolidinyl)methyl)uracil hydrochloride in a molar ratio of 1:0.5 at a dose of 20 to 80 mg/m.sup.2/day in terms of FTD in 2 to 4 divided portions per to patients in need of the treatment.
Inventor(s):	Emura; Tomohiro (Hanno, JP), Mita; Akira (Tokyo, JP)
Assignee:	TAIHO PHARMACEUTICAL CO., LTD. (Tokyo, JP)
Application Number:	14/985,148
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent RE46284
Patent Claim Types: see list of patent claims	Use; Composition; Dosage form;
Patent landscape, scope, and claims:	United States Patent RE46284: A Detailed Analysis of Scope, Claims, and Patent Landscape Introduction The United States Patent RE46284, titled "Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor," is a reissue patent that plays a crucial role in the treatment of various types of cancer. This patent is associated with the drug TAS-102, which is marketed under the brand name Lonsurf. Here, we will delve into the scope, claims, and the broader patent landscape surrounding this invention. Background of the Patent Reissue Application The patent RE46284 is a reissue application of U.S. Pat. No. 7,799,783, which was issued from application Ser. No. 11/042,059 filed on January 26, 2005. This reissue indicates that the original patent has been re-examined and potentially modified to clarify or broaden its claims[4]. Scope of the Patent Therapeutic Use The patent covers a method for treating cancer using a composition containing α, α, α-trifluorothymidine (FTD) and a thymidine phosphorylase inhibitor (TPI). FTD is a nucleoside analogue that has been shown to have significant therapeutic effects against various cancers. The inclusion of TPI prevents the degradation of FTD, allowing for its oral administration and maintaining its blood concentration[4]. Types of Cancer Treated The method outlined in the patent is intended for treating a wide range of cancers, including but not limited to: Esophageal Gastric Liver Gallbladder-bile duct Pancreatic Colorectal Head and neck Lung Breast Cervical Ovarian Bladder Prostate cancers Cancer of the testicles Soft tissue and bone sarcomas Skin cancer Malignant lymphoma Leukemia Brain tumors The patent particularly emphasizes its application in malignant solid cancers such as gastric, pancreatic, breast, colorectal, head and neck, gallbladder-bile duct, and lung cancers[4]. Claims of the Patent Key Components The patent claims revolve around the administration of a composition containing FTD and TPI. Here are the key components: α, α, α-Trifluorothymidine (FTD): A nucleoside analogue with a trifluoromethyl group substitution at the 5-position of thymidine. Thymidine Phosphorylase Inhibitor (TPI): Specifically, 5-chloro-6-(1-(2-iminopyrrolidinyl)methyl)uracil hydrochloride, which prevents the degradation of FTD and allows for its oral administration[4]. Administration Method The method involves orally administering the composition in a specific molar ratio of FTD to TPI, typically 1:0.5. This ratio is crucial for maintaining the therapeutic efficacy of FTD by preventing its premature degradation[4]. Patent Landscape Related Patents The patent RE46284 is part of a broader portfolio of patents related to Lonsurf, which includes multiple patents covering various aspects such as: Methods for treating cancer patients with severe renal impairment[1]. Stable crystal forms of tipiracil hydrochloride and their crystallization methods[1]. These patents collectively protect the intellectual property surrounding the drug TAS-102, ensuring its exclusivity in the market for treating specific types of cancer. Competitor Landscape The patent landscape in the oncology sector is highly competitive, with multiple pharmaceutical companies and research institutions actively involved in drug discovery and development. The use of patent landscaping tools and knowledge graphs, as described in other studies, helps in identifying trends and applications in patents for various diseases, including cancer[3]. Regulatory and Legal Aspects The patent is subject to regulatory oversight, particularly by the FDA. The listing of patents in the Orange Book and disputes over patent claims and use codes are common in the pharmaceutical industry. The Hatch-Waxman Act and accompanying FDA regulations govern these disputes, ensuring that there are clear procedures for resolving issues related to the scope and validity of listed patents[2]. Clinical and Market Impact Approval and Use TAS-102, the drug associated with this patent, has been approved for the treatment of metastatic colorectal cancer and metastatic gastric or gastroesophageal junction adenocarcinoma in patients who have been previously treated with certain types of chemotherapy. The approval is based on clinical trials that demonstrated the efficacy and safety of the drug in these patient populations[1]. Market Dominance The exclusive rights granted by this patent and related patents ensure that Lonsurf remains a dominant player in the market for treating these specific types of cancer. This exclusivity is crucial for the drug's commercial success and for the company's ability to recoup its investment in research and development. Key Takeaways Therapeutic Use: The patent covers a method for treating various types of cancer using a composition containing FTD and TPI. Scope: The method is applicable to a wide range of cancers, with a focus on malignant solid cancers. Claims: The patent claims center around the administration of FTD and TPI in a specific molar ratio. Patent Landscape: The patent is part of a broader portfolio protecting the drug TAS-102, with multiple related patents and a competitive landscape in the oncology sector. Regulatory and Legal Aspects: The patent is subject to FDA regulations and the Hatch-Waxman Act, with clear procedures for resolving disputes over patent claims. FAQs What is the primary use of the drug associated with United States Patent RE46284? The primary use of the drug associated with this patent is the treatment of various types of cancer, including metastatic colorectal cancer and metastatic gastric or gastroesophageal junction adenocarcinoma. What are the key components of the composition described in the patent? The key components are α, α, α-trifluorothymidine (FTD) and a thymidine phosphorylase inhibitor (TPI), specifically 5-chloro-6-(1-(2-iminopyrrolidinyl)methyl)uracil hydrochloride. How is the composition administered? The composition is administered orally in a specific molar ratio of FTD to TPI, typically 1:0.5. What is the significance of the thymidine phosphorylase inhibitor in the composition? The thymidine phosphorylase inhibitor prevents the degradation of FTD, allowing for its oral administration and maintaining its therapeutic efficacy. How does this patent fit into the broader patent landscape for cancer treatments? This patent is part of a broader portfolio of patents related to Lonsurf, protecting the intellectual property surrounding the drug TAS-102 and ensuring its exclusivity in the market for treating specific types of cancer. What regulatory frameworks govern disputes related to this patent? The patent is subject to FDA regulations and the Hatch-Waxman Act, which provide clear procedures for resolving disputes over patent claims and use codes. Sources Drug Patent Watch - Lonsurf Drug Patent Profile United States District Court - In the United States District Court - District of Delaware BioRxiv - A novel approach to understand patents from the drug discovery perspective Google Patents - Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor More… ↓ ⤷ Subscribe

Drugs Protected by US Patent RE46284

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Taiho Oncology	LONSURF	tipiracil hydrochloride; trifluridine	TABLET;ORAL	207981-001	Sep 22, 2015	AB	RX	Yes	No	⤷ Subscribe	⤷ Subscribe				TREATMENT OF ADULTS WITH METASTATIC GASTRIC OR GJA PREVIOUSLY TREATED WITH AT LEAST TWO PRIOR LINES OF CHEMOTHERAPY THAT INCLUDED A FLUOROPYRIMIDINE, A PLATINUM, EITHER A TAXANE OR IRINOTECAN, AND IF APPROPRIATE, HER2/NEU-TARGETED THERAPY	⤷ Subscribe
Taiho Oncology	LONSURF	tipiracil hydrochloride; trifluridine	TABLET;ORAL	207981-001	Sep 22, 2015	AB	RX	Yes	No	⤷ Subscribe	⤷ Subscribe				TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER WHO HAVE BEEN PREVIOUSLY TREATED WITH FLUOROPYRIMIDINE-, OXALIPLATIN- AND IRINOTECAN-BASED CHEMOTHERAPY, AN ANTI-VEGF BIOLOGICAL THERAPY, AND IF RAS WILD-TYPE, AN ANTI-EGFR THERAPY	⤷ Subscribe
Taiho Oncology	LONSURF	tipiracil hydrochloride; trifluridine	TABLET;ORAL	207981-001	Sep 22, 2015	AB	RX	Yes	No	⤷ Subscribe	⤷ Subscribe				TREATMENT OF METASTATIC COLORECTAL CANCER ALONE OR WITH BEVACIZUMAB IN PATIENTS PREVIOUSLY TREATED WITH FLUOROPYRIMIDINE-, OXALIPLATIN- AND IRINOTECAN-BASED CHEMOTHERAPY, AN ANTI-VEGF BIOLOGICAL THERAPY, AND IF RAS WILD-TYPE, AN ANTI-EGFR THERAPY	⤷ Subscribe
Taiho Oncology	LONSURF	tipiracil hydrochloride; trifluridine	TABLET;ORAL	207981-002	Sep 22, 2015	AB	RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe				TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER WHO HAVE BEEN PREVIOUSLY TREATED WITH FLUOROPYRIMIDINE-, OXALIPLATIN- AND IRINOTECAN-BASED CHEMOTHERAPY, AN ANTI-VEGF BIOLOGICAL THERAPY, AND IF RAS WILD-TYPE, AN ANTI-EGFR THERAPY	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent RE46284

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1849470	⤷ Subscribe	PA2017024	Lithuania	⤷ Subscribe
European Patent Office	1849470	⤷ Subscribe	300889	Netherlands	⤷ Subscribe
European Patent Office	1849470	⤷ Subscribe	CA 2017 00036	Denmark	⤷ Subscribe
European Patent Office	1849470	⤷ Subscribe	122017000052	Germany	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.